Scienta Lab is a TechBio company co-founded in 2021 by Camille Bouget, Vincent Bouget and Julien Duquesne. The company develops EVA, a proprietary multimodal foundation model dedicated to Immunology & Inflammation. As part of its first use case, EVA leverages pre-clinical data of new therapeutic assets to provide early-stage evidence of human clinical efficacy. By significantly improving the clinical trial success rates of innovative, best-in-class treatments, Scienta Lab's innovation is paving the way for AI-powered precision immunology. Scienta Lab raised 4M€ from VCs and international business angels in 2023.
Scienta Lab
What is the role of Scienta Lab in Autopix
In AutoPix, Scienta Lab will co-lead the development of an imaging foundation model dedicated to arthritis.
Q&A
In what part of the patient journey will your institution most likely contribute?
Scienta Lab, in partnership with the University of Vienna, is co-leading WP7 to advance precision medicine for arthritis. One of the key challenges in rheumatology has been the limited availability and variability of patient data, hindering the progress of personalised treatments. To address this issue, Scienta Lab will co-lead the creation of a foundational model specifically designed for arthritis. This model will pave the way for advanced machine learning algorithms capable of extracting valuable insights from limited datasets and enhancing their ability to generalise across diverse patient populations.
What long-term impacts do you envision of your contribution?
Scienta Lab aims to facilitate the use of machine learning on complex and diverse datasets, overcoming a key barrier in precision medicine for arthritis. In the long term, this will enable more accurate diagnostics, personalised treatment strategies, and improved patient outcomes. Additionally, by integrating imaging and molecular data, these models will enhance disease modelling, supporting targeted therapeutic intervention strategies in arthritis and potentially other autoimmune conditions.
Why is it so important?
Current approaches in precision medicine for autoimmune diseases are limited by fragmented and sparse patient data, hindering accurate diagnostics and personalised treatments. By developing advanced foundation models that integrate diverse data types, Scienta Lab addresses this challenge, enabling machine learning algorithms to extract meaningful insights and generalise across varied patient populations. This will not only improve patient outcomes through tailored therapies but also accelerate drug development, ultimately transforming care for arthritis and other autoimmune conditions. By advancing these models, Scienta Lab is laying the groundwork for a new era of precision medicine, where more accurate diagnostics and personalised treatments become a reality for patients with autoimmune diseases.
Contact
Vincent Bouget
Co-founder and Chief Scientific Officer